Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Update

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) was the target of a large decrease in short interest in January. As of January 30th, there was short interest totaling 1,318,481 shares, a decrease of 14.7% from the January 15th total of 1,546,371 shares. Based on an average daily trading volume, of 999,462 shares, the short-interest ratio is presently 1.3 days. Approximately 19.6% of the shares of the stock are short sold. Approximately 19.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 999,462 shares, the short-interest ratio is presently 1.3 days.

Insider Activity at Greenwich LifeSciences

In related news, CEO Snehal Patel purchased 4,600 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The shares were acquired at an average price of $8.37 per share, with a total value of $38,502.00. Following the purchase, the chief executive officer directly owned 5,588,102 shares in the company, valued at $46,772,413.74. This represents a 0.08% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last ninety days, insiders purchased 20,600 shares of company stock worth $378,669. 51.47% of the stock is owned by company insiders.

Hedge Funds Weigh In On Greenwich LifeSciences

Institutional investors have recently modified their holdings of the business. Man Group plc acquired a new position in shares of Greenwich LifeSciences in the 4th quarter valued at approximately $590,000. Barclays PLC lifted its stake in Greenwich LifeSciences by 11.8% in the fourth quarter. Barclays PLC now owns 9,744 shares of the company’s stock valued at $205,000 after buying an additional 1,030 shares in the last quarter. State Street Corp boosted its holdings in shares of Greenwich LifeSciences by 19.3% in the fourth quarter. State Street Corp now owns 97,777 shares of the company’s stock valued at $2,054,000 after buying an additional 15,831 shares during the period. Wells Fargo & Company MN increased its position in shares of Greenwich LifeSciences by 109.6% during the fourth quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock worth $165,000 after acquiring an additional 4,102 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Greenwich LifeSciences during the fourth quarter worth $203,000. Institutional investors own 4.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. HC Wainwright upped their target price on shares of Greenwich LifeSciences from $39.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Monday, December 29th. Finally, Wall Street Zen raised shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, December 27th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Greenwich LifeSciences presently has an average rating of “Hold” and a consensus price target of $47.50.

Greenwich LifeSciences Price Performance

Shares of Greenwich LifeSciences stock traded down $0.80 during trading on Wednesday, hitting $24.44. 77,056 shares of the company were exchanged, compared to its average volume of 541,974. The firm has a market capitalization of $338.51 million, a P/E ratio of -16.64 and a beta of 1.48. The firm’s fifty day moving average price is $22.67 and its 200 day moving average price is $14.62. Greenwich LifeSciences has a 1-year low of $7.78 and a 1-year high of $34.10.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.